Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R)


Novo Nordisk A/S: Tresiba(R) (insulin degludec) and Ryzodeg(R) (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities

BAGSVAERD, DENMARK -- (Marketwire) -- 10/19/12 --

Company Announcement No 66 / 2012: http://hugin.info/2013/R/1650358/532183.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:


 
(i)  the releases contained herein are protected by copyright and
     other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1650358]

Further information:

Media: Mike Rulis Tel: (+45) 3079 3573 mike@novonordisk.com

Investors:

Kasper Roseeuw Poulsen Tel: (+45) 4442 4303 krop@novonordisk.com

Frank Daniel Mersebach Tel: (+45) 4442 0604 fdni@novonordisk.com

Lars Borup Jacobsen Tel: (+45) 3075 3479 lbpj@novonordisk.com

In North America:

Ambre Morley Tel: (+1) 609 216 5240 abmo@novonordisk.com

Jannick Lindegaard Tel: (+1) 609 786 4575 jlis@novonordisk.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement